Delivery Order SPE2DB22D3011-SPE2DB25FQ2MH
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order by the Defense Logistics Agency for $8,526.60 to supply DESCOVY 200-25 mg tablets in quantities of 30 units. The contract, awarded on August 27, 2025, with an ultimate completion date of August 28, 2025, utilizes firm fixed pricing and is not designated as a set-aside contract. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $3,303.18 on August 28, 2025, for the supply of DESCOVY 200-25 mg tablets in quantities of 30 units. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 29, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of DESCOVY 200-25 MG tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $21,761.46 and is scheduled for completion by July 31, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery at its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of DESCOVY 200-25 mg tablets (30-count units) with a ceiling value of $19,468.34. This firm fixed-price delivery order, with an ultimate completion date of August 26, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract was competitively awarded with no set-aside designation and will...
- The Defense Logistics Agency awarded a $15,047.95 delivery order to AmerisourceBergen Drug Corp for DESCOVY 200-25 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This is a firm fixed price, non-set-aside contract that leverages AmerisourceBergen's existing pharmaceutical supply infrastructure. The place of performance is the contractor's corporate office in Conshohocken, Pennsylvania. As a child contract under AmerisourceBergen's larger...
- This delivery order, valued at $4,138.47, awards AmerisourceBergen Drug Corp the supply of DESCOVY 200-25 mg tablets in quantities of 30 units. The contract, issued by the Defense Logistics Agency under the Department of Defense, is a non-set-aside, competitively awarded delivery order with firm fixed pricing. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of August 1, 2025. This delivery order is issued as a child contract under...
- On July 28, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $134,582.59 to AmerisourceBergen Drug Corp for DESCOVY 200-25MG in a 30-count supply. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location through the ultimate completion date of August 22, 2025. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $27,577.96 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of DESCOVY 200-25 mg tablets in quantities of 30. This competitive award, which will be completed by August 12, 2025, represents a firm fixed-price transaction with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $5,662.17 to AmerisourceBergen Drug Corp for the supply of DESCOVY 200-25 mg tablets in quantities of 30 units. This competitively awarded, firm fixed price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which is valued at $999,999,999.00 and extends through December 2026. The pharmaceutical product will be delivered to AmerisourceBergen's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 7, 2025, for $10,523.69 to supply Descovy 200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procurement procedures. The contract is a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ2MHDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency (DLA) on August 28, 2025, valued at $37,182.02. The contract calls for the supply of DESCOVY 200-25 mg tablets in quantities of 30 units, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger prime indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen's underlying prime IDC, designated SPE2DX and valued at $999,999,999.00 through December 2026, serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. This delivery order for DESCOVY, a prescription antiretroviral medication, reflects the company's critical role in fulfilling pharmaceutical procurement requirements for the Defense Health Agency and other federal healthcare systems through the flexible DLA contracting framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $37.2k | 8/28/25 |